TENX实时信号 | 通过Getagraph.com最大化利润

购买 117649 min ago

@ $4.72

发出时间: 13 Feb 2024 @ 22:30

回报率: -18.66%

上一信号: Feb 12 - 23:27

上一信号: 出售

回报率: -6.14 %

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	11 652.00
平均成交量	355 937
市值	7.52M
EPS	$0 ( 2024-04-01 )
下一个收益日期	( $-2.40 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0290 (0.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-11	Hoffman Lawrence R	Sell	0	Common Stock
2022-09-21	Rich Stuart	Buy	1 909 585	Common Stock
2022-09-21	Rich Stuart	Sell	1 909 585	Common Stock
2022-08-11	Doogan Declan	Sell	567 871	Common Stock
2022-06-09	Rich Stuart	Buy	100 000	Stock Option (right to buy)

INSIDER POWER
20.96
Last 92 transactions
Buy: 35 341 052 \| Sell: 26 670 670

音量相关性

長: -0.04 (neutral)

短: -0.48 (neutral)

Signal:(53.064) Neutral

Tenax Therapeutics Inc 相关性

10 最正相关
VRM	0.947
LGVN	0.94
EBIX	0.939
VRAY	0.938
RIDE	0.938
TVACW	0.936
AGRI	0.935
SRNGW	0.933
KSPN	0.932
REVB	0.927

10 最负相关
TIOA	-0.943
MSDA	-0.939
NVCN	-0.938
BRIVU	-0.937
SILK	-0.934
SGII	-0.932
BRIV	-0.929
PRAX	-0.927
ALOR	-0.921
STAY	-0.919

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tenax Therapeutics Inc 相关性 - 货币/商品

-0.53
( weak negative )

-0.35
( neutral )

0.00
( neutral )

-0.78
( moderate negative )

0.29
( neutral )

Tenax Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-7 570.00 (0.00 %)
EPS:	$-31.04

FY	2023
营收:	$0
毛利润:	$-7 570.00 (0.00 %)
EPS:	$-31.04

FY	2022
营收:	$0
毛利润:	$-113 332 (0.00 %)
EPS:	$-600.46

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.580

Financial Reports:

No articles found.

Tenax Therapeutics Inc

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.